DOCETAXEL
| Brand name | BEIZRAY |
|---|---|
| Active ingredient | DOCETAXEL |
| Strength | 80MG/4ML (20MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | October 2024 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11419842 | May 2036 | product |
| 12090134 | May 2036 | product |
| 12090135 | May 2036 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.